Breast cancer is one of the most common malignancies worldwide, and this is no different in the Arab World. In this review, we attempt to highlight some unique aspects of breast cancer and breast cancer care in the Arab region. Although Arab countries have much in common and are grouped into one region, it is important to note that there are significant social, economic, and political stability differences that have great implications on breast cancer care and health care systems in general. Accurate data on breast cancer incidence rate, stage at presentation, and treatment outcomes are lacking in most Arab countries. However, breast cancer is known to present at a younger age and with more advanced-stage compared to Western societies.
Although high-quality breast cancer care is available at some comprehensive cancer centers, this is the exception. The social, financial, and political instability of many countries plays a major role in impeding the development of standardized structured programs capable of providing high-quality care, as resources are often allocated to more emergent healthcare needs. Opportunities exist to scale up local health care systems to provide a better quality of care across the cancer care continuum; from early detection to palliative care and survivorship.
- Breast cancer
- Arab world
- Breast cancer screening
- Cancer care
- Cancer control
Breast cancer is the most common malignancy diagnosed in females worldwide [1, 2], and despite enormous efforts at early detection and the presence of many new and evolving treatments, it remains the leading cause of cancer-related mortality in females as well [3, 4]. The estimated incidence of new breast cancer cases was around 2.26 million in 2020, with a cumulative of 685,000 breast cancer-related deaths worldwide in that year . Cancer in general, and breast cancer in particular, is a growing health issue in the Arab World.
The Arab world comprises 22 countries with memberships in the Arab League, spanning across the Middle East and North Africa. Unfortunately, many of these countries are troubled with financial and political instabilities, some being active war zones. Although there are significant linguistic and cultural ties and similarities, there are also many significant social and economic differences in addition to some ethnic and genetic variations. According to the World Bank ranking, some Arab countries are ranked as high income (i.e., Gulf countries) while others are ranked as low income (i.e., Syria, Sudan, and Somalia), with many in between . These differences have many implications on education, social perspectives, and health care system development and organization in their respective countries, in addition to direct effects on the policies prioritizing health care resources’ allocations.
In the following review, we attempt to discuss the unique features of breast cancer and breast cancer care within Arab Countries. Although the Arab World is viewed as a single region, it is important, as mentioned above, to understand data in the context of the vast variations in political stability and social and economic development variations between the different countries.
22.2 Epidemiology of Breast Cancer in Arab Countries
The exact prevalence and incidence of breast cancer cases in the Arab world are not known due to the lack of well-structured cancer registries in most of these countries. In addition, mortality registries and disease-specific mortality records are lacking and largely unknown. Data on breast cancer in the Arab World mostly stem from literature reviews of published data from individual countries in the forms of retrospective data reports and published individual institution records, many of which are high-quality reports published in peer-reviewed journals.
From available data from the years 2010, 2013, and most recently 2020, breast cancer is thought to be the most common malignancy diagnosed in Arab women, estimating somewhere between 14–42% of all tumors [6, 7] in some reports, and between 17.7–19% of all new cancers in others , depending on individual countries and type of reports reviewed. Age-standardized incidence also varies between countries and ranges between 9.5 and 50 cases per 100,000 women per year . Although the incidence of new cases and burden of the disease seem to be lower than that in the more developed Western World and the global averages in general, the incidence has been rising over the past few decades [7, 9, 10], and the rate of increase seems to be similar to the global trend . This increase can be partly attributed to advances in medical care and diagnosis, implementation of limited screening programs leading to better diagnosis of previously unidentified cases, in addition to better reporting. However, this can also be partially attributed to an actual increase in disease burden due to demographic and lifestyle changes. More Arab societies and women are being influenced by Westernized lifestyles such as dietary habits, delayed age at marriage and first pregnancies, lower reproductive rates, in addition to more smoking and more use of oral contraceptives and Hormonal Replacement Therapies (HRTs) [9,10,11].
The median age at the time of diagnosis of women with breast cancer in the Arab world is almost a decade younger than in industrialized countries such as Europe and the USA. It is estimated in different reports to be around 48–52 years compared to around 63 years, with somewhat between one-half and two-thirds of diagnosed individuals below the age of 50 [7, 10, 12, 13], compared to only about 23% below the age of 50 in the United States . This can largely be attributed however to the young population structure. In addition to the younger median population age, elderly Arab women are also likely to be under-represented and more frequently underdiagnosed in relevant analyses, as they are less likely to obtain a mammogram or seek medical care for breast disease [15, 16].
22.3 Breast Cancer Screening and Early Detection
Unfortunately, most Arab countries lack a structured universal screening program. Several awareness campaigns take place on different occasions, especially in the month of October, Breast Cancer Awareness Month. These kinds of campaigns take place in the form of media interventions, advertisements, public physician interviews, and awareness lectures/speeches. Although some promising screening program initiatives have been recently raised in some countries, most women who undergo screening mammograms are either self-motivated, advised by afflicted family members, or by motivated physicians. These screening procedures are, however, not consistently covered by medical insurances. In addition, there is a lack in the number and distribution of mammography centers, and trained personnel, and the existing units are not universally monitored for quality, results, and reporting by any overseeing agency [10, 17].
Although some researchers and experts have suggested that the younger median age at the time of initial breast cancer diagnosis in the Arab World should trigger a younger age for breast cancer screening advice and target population [7, 10], others have challenged this suggestion since the median age of diagnosis in a population is thought to be less relevant than age-specific incidence when forming policies and recommendations [9, 18, 19].
22.4 Diagnosis and Stage
More women in the Arab World present with more advanced diseases compared to Western countries. More patients are diagnosed with larger tumors, positive lymph nodes, and inflammatory breast cancer, and metastatic diseases [17, 20,21,22,23,24]. Reports assessing tumor size at the time of initial presentation have estimated that as high as 70–80% of tumors were more than 2 cm in diameter [20, 21]. Similarly, lymph node involvement at the time of initial diagnosis has also been reported at high percentages of 50–80% [22,23,24].
Inflammatory breast cancer, being the most aggressive form of non-metastatic breast cancer, is associated with the highest mortality. It is considered rare and reported in only 1–2% of new breast cancer diagnoses in the United States [25, 26]. In the Arab world, reported rates are as high as 11% of newly diagnosed cases [27, 28]. Unfortunately, the same applies to a higher incidence of de novo metastatic disease with rates as high as 13.4% compared to 6% [17, 29, 30].
There are many proposed reasons for the late diagnosis and advanced initial stage. Although genetic, adverse molecular variations and racial factors have been proposed; delayed presentation and late seeking of medical advice are likely to play a major role, as well. In addition to impaired access to adequate care, several psycho-social aspects also influence women’s decisions to delay diagnosis and treatment. This is discussed in an upcoming section.
22.5 Obstacles to High-Quality Standardized Management
One major obstacle to optimal cancer care in general and breast cancer care in particular in the Arab region is the social, financial, and political instability of many countries in this region. Some countries are directly inflicted by wars, leading to the routing of health care resources away from many Non-Communicable Diseases (NCDs) such as cancer. With these wars and conflicted areas, there is a growing refugee crisis, as many people move from politically unstable areas to financially unstable countries. There has been an increasing awareness about this issue in recent years . The repercussions of the Syrian crisis and refugee cancer care status have been comprehensively reviewed in several recent articles, for example [32,33,34,35]. Cancer care results in a significant strain on health care systems in hosting countries, both financially and ethically. Although there continue to be international medical relief efforts, both through non-governmental and governmental agencies, the costly nature of cancer care, and the need to prioritize already limited resources, leads in many instances to suboptimal care or even neglect. The need for an increase in funding, in addition to multidisciplinary care teams and evidence-based standard operating procedures in these areas, is highly needed to coordinate and prioritize care and resources, but this is yet to be established [32, 33].
Although the role of multidisciplinary care is well established in cancer care to ensure the best available management approach and treatment outcomes , this is seldom available or practiced in the majority of healthcare systems in the Arab region. With few exceptions, many, even though not all, Arab countries lack universal access to comprehensive cancer care centers or patient care by specialized cancer care teams with the adequate advanced oncologic training and expertise needed to provide required complicated treatment plans, leading to suboptimal cancer care. As an example, the rate of modified radical mastectomies in Arab countries is much higher than that in internationally reported literature, reaching up to about two-thirds of cases [10, 20, 37,38,39,40,41], and is as high as 88% in some reports from Syria . Around 21% of patients undergoing modified radical mastectomy will develop clinically significant lymphedema , a complication that could potentially be avoided in a subset of patients.
One important reason for a high rate of radical procedures in breast cancer is the advanced stage at the time of disease presentation. However, many of these procedures could otherwise be potentially avoidable, and some reasons for this unexpected high rate have been explored in published reports. Lack of enough radiation therapy centers and accelerator machines in some countries are additional contributing factors . Professional experience in breast-conserving surgery, sentinel lymph node sampling, skin-sparing and nipple-sparing mastectomies is not available in most of the low-income Arab countries and contributes to a higher rate of more radical procedures. Similarly, reconstructive surgeries are not always available, and when they are, not consistently covered by insurance .
Cost of cancer treatment in general, and new targeted and immunotherapy in breast cancer, in particular, is a major issue in The Arab World. There has been an approval of several expensive novel agents for breast cancer in recent years. Although these treatments might be readily available in some high-income Arab countries, access to these medications and financial coverage by governmental and non-governmental insurance plans and agencies is limited in many others.
Cost and financial burden also play a role in the limitation of many other aspects of breast cancer care in the Arab world. One major example is genetic testing and counseling. Almost 10–15% of breast cancers worldwide are thought to be inherited , and genetic testing for the most prevalent cancer genes such as BRCA1 and BRCA2 has become standard in many countries and is recommended by international guidelines . However, this is not widely practiced or standardized in most Arab countries, reports from these areas are limited, and little is known about the role of these and other genetic mutations in Arab patients, although some reports suggest a higher prevalence in Arab women . One report from Jordan, from a single institution’s experience, showed that about 14% of screened high-risk breast cancer patients had a deleterious mutation . Two different studies in Tunisia showed contrasting variable results for BRCA1 testing in selected populations with a reported prevalence of 16% and 38% [49, 50]. Reports from Lebanon, Morocco, Egypt, and a few other countries have also shown variable results [51,52,53,54,55,56,57], likely reflecting variations in selection criteria for testing referrals, different testing techniques, and small numbers of patients enrolled . This lack of standardized and universal testing contributes to limitations of proper screening and follow-up in patients and their family members, further leading to late diagnoses and advanced disease stage at presentation. Cost and financial burden are not the only factors contributing to inconsistent genetic testing and counseling in the Arab populations, however, with psycho-social aspects also playing a significant role in patient acceptance of testing, and sharing of results.
22.6 Unique Psycho-Social Aspects of Breast Cancer in the Arab World
Unfortunately, even in this time and age, cancer in general and breast cancer, in particular, is associated with significant social stigmatization in many countries and societies in the Arab world, regardless of socio-economic and educational development in these countries. Women diagnosed with breast cancer often describe a feeling of shame or guilt, and fear of being blamed for having cancer, as at times, it is regarded as a sign of punishment for undisclosed sins . In addition, there is added stress of fearing they can pass their illness to their daughters, or that the females in the family are considered potentially diseased, and thus decreasing their chances of future marriage. This is more pronounced in less urban parts of the Arab world where arranged marriages and consanguinity are still a significant part of these societies. Light has been shed on these issues in several different reports from the area [58,59,60,61,62,63,64]. The importance of this particular aspect stems from the fact that this leads many women to conceal their illness, delay seeking medical advice, and delay treatment despite active symptoms and this results in late presentations and more advanced disease stages at the time of diagnosis. In addition, this is an important factor hampering the progress of national efforts for the promotion and implementation of screening programs. Much progress has been made over the past few years in awareness campaigns in many parts of the Arab world, and much more is still needed.
22.7 Conclusion and Future Directions
Breast cancer is the most common cancer diagnosed among women worldwide as well as in Arab countries. More advanced-stage and younger age at presentations are common features in the region. Resources and staff availability are quite variable. Opportunities exist to up-scale the quality of care provided and that should reflect positively on treatment outcomes.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021b;71(3):209–49. https://doi.org/10.3322/caac.21660.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.
GBD 2015 Eastern Mediterranean Region Cancer Collaborators. Burden of cancer in the Eastern Mediterranean Region, 2005–2015: findings from the global burden of disease 2015 study. Int J Public Health. 2018;63:151–64.
The World Bank: Countries Data. https://data.worldbank.org/country
El Saghir SN, Abulkhair O. Epidemiology, prevention and management guidelines for breast cancer in Arab countries. Pan Arab J Oncol. 2010;3:12–8.
Chouchane L, Boussen H, Sastry K. Breast cancer in Arab populations: molecular characteristics and disease management implications. Lancet Oncol. 2013;14(10):e417–24.
Fearon D, Hughes S, Brearly S. Experiences of breast cancer in Arab countries: a thematic synthesis. Qual Life Res. 2020;29(2):313–24.
Hashim M, Al-Shamsi F, Al-Marzooqi N, Al-Qasemi S, Mokdad A, Khan G. Burden of breast cancer in the Arab world: findings from global burden of disease, 2016. J Epidemiol Glob Health. 2018;1(1–2):54–8.
Al Saghir N, Khalil M, Eid T, et al. Trends in epidemiology and management of breast cancer in developing Arab countries: a literature and registry analysis. Int J Surg. 2007 Aug;5(4):225–33.
Ravichandran K, Al-Zahrani AS. Association of reproductive factors with the incidence of breast cancer in Gulf Cooperation Council countries. East Mediterr Health J. 2009;15:612–21.
Najjar H, Easson A. Age at diagnosis of breast cancer in Arab nations. Int J Surg. 2010;8:448–52.
SEER cancer stat facts: female breast cancer. National Cancer Institute. Bethesda, MD. https://seer.cancer.gov/statfacts/html/breast.html
Smigal C, Jemal A, Ward E, Cokkinides V, Smith R, Howe HL, et al. Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin. 2006;56:168–83.
Mellon S, Gauthier J, Cichon M, Hammad A, Simon MS. Knowledge, attitude, and beliefs of Arab-American women regarding inherited cancer risk. J Genet Couns. 2013;22:268–76.
Brown R, Kerr K, Haoudi A, Darzi A. Tackling cancer burden in the Middle East: Qatar as an example. Lancet Oncol. 2012;13:e501–8.
Abdel-Razeq H, Mansour A, Jaddan D. Breast cancer care in Jordan. JCO Glob Oncol. 2020;6:260–8.
Corbex M, Harford JB. Perspectives on breast cancer in Arab populations. Lancet Oncol. 2013;14:e582.
Harford JB. Breast-cancer early detection in low-income and middle-income countries: do what you can versus one size fits all. Lancet Oncol. 2011;12:306–12.
Fakhro AE, Fateha BE, Al-Asheeri N, Al-Ekri SA. Breast cancer: patient characteristics and survival analysis at Salmaniya Medical Complex, Bahrain. East Mediterr Health J. 1999;5:430–9.
Missaoui N, Jaidene L, Abdelkrim SB, et al. Breast cancer in Tunisia: clinical and pathological findings. Asian Pac J Cancer Prev. 2011;12:169–72.
El-Zaemey S, Nagi N, Fritschi L, Heyworth J. Breast cancer among Yemeni women using the National Oncology Centre Registry 2004–2010. Cancer Epidemiol. 2012;36:249–53.
Ezzat AA, Ibrahim EM, Raja MA, Al-Sobhi S, Rostom A, Stuart RK. Locally advanced breast cancer in Saudi Arabia: high frequency of stage III in a young population. Med Oncol. 1999;16:95–103.
Zidan J, Sikorsky BW, Sharabi A, Friedman E, Steiner M. Differences in pathological and clinical features of breast cancer in Arab as compared to Jewish women in Northern Israel. Int J Cancer. 2012;131:924–9.
Goldner B, Behrendt C, Schollhammer H, Lee B, Chen S. Incidence of inflammatory breast cancer in women, 1992–2009, United States. Ann Surg Oncol. 2014;21(4):1267–70.
Anderson WF, Schairer C, Chen BE, Hance KW, Levine PH. Epidemiology of inflammatory breast cancer (IBC). Breast Dis. 2005–2006;22:9–23.
Boussen H, Bouzaiene H, Ben Hassouna J, Gamoudi A, Benna F, Rahal K. Infl ammatory breast cancer in Tunisia: reassessment of incidence and clinicopathological features. Semin Oncol. 2008;35:17–24.
Soliman AS, Banerjee M, Lo AC, et al. High proportion of inflammatory breast cancer in the population-based cancer registry of Gharbiah, Egypt. Breast J. 2009;15:432–4.
National Cancer Institute: Cancer stat facts: Female breast cancer. https://seer.cancer.gov/statfacts/html/breast.html
Cancer Research: UK Breast cancer incidence (invasive) statistics. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-bycancer-type/breast-cancer/incidence-invasive
El Saghir NS, Pérez S, de Celis E, Fares JE, Sullivan R. Cancer care for refugees and displaced populations: Middle East conflicts and global natural disasters. Am Soc Clin Oncol Educ Book. 2018;23(38):433–40.
Spiegel PB, Cheaib JG, Aziz SA, Abrahim O, Woodman M, Khalifa A, Jang M, Mateen FJ. Cancer in Syrian refugees in Jordan and Lebanon between 2015 and 2017. Lancet Oncol. 2020 May;21(5):e280–91.
Spiegel P, Khalifa A, Mateen FJ. Cancer in refugees in Jordan and Syria between 2009 and 2012: challenges and the way forward in humanitarian emergencies. Lancet Oncol. 2014 Jun;15(7):e290–7.
Abdul-Khalek RA, Guo P, Sharp F, Gheorghe A, Shamieh O, Kutluk T, Fouad F, Coutts A, Aggarwal A, Mukherji D, Abu-Sittah G, Chalkidou K, Sullivan R, R4HC-MENA Collaboration. The economic burden of cancer care for Syrian refugees: a population-based modelling study. Lancet Oncol. 2020;21(5):637–44.
Akik C, Ghattas H, Mesmar S, Rabkin M, El-Sadr WM, Fouad FM. Host country responses to non-communicable diseases amongst Syrian refugees: a review. Confl Heal. 2019 Mar;22(13):8.
Anderson BO, Braun S, Carlson RW, et al. Overview of breast health care guidelines for countries with limited resources. Breast J. 2003;2(Suppl. 9):S42e5035.
Elattar I, Zaghloul M, Omar A, Mokhtar N. Breast cancer in Egypt. Cairo: National Cancer Institute of Egypt, NCI Cairo Publications; 2007.
Abdel-Fattah M, Lotfy NS, Bassili A, Anwar M, Mari E, Bedwani R, et al. Current treatment modalities of breast cancer patients in Alexandria, Egypt. Breast. 2001;10(6):523e9.
Al-Moundhri M, Al-Bahrani B, Pervez I, et al. The outcome of treatment of breast cancer in a developing country-Oman. Breast. 2004;13:139e45.
Nissan A, Spira RM, Hamburger T, et al. Clinical profile of breast cancer in Arab and Jewish women in the Jerusalem area. Am J Surg. 2004;188:62e7.
Maalej M, Frikha H, Ben Salem S, et al. Breast cancer in Tunisia: clinical and epidemiological study. Bull Cancer. 1999;86:302–6.
Mzayek F, Asfar T, Rastam S, Maziak W. Neoplastic diseases in Aleppo, Syria. Eur J Cancer Prev. 2002;11(5):503–7.
Morcos BB, Al Ahmad F, Anabtawi I, et al. Lymphedema: a significant health problem for women with breast cancer in Jordan. Saudi Med J. 2013;34:62–6.
Semaan S. Breast cancer in Syria. Pan Arab Cancer Congress Proceedings, Damascus, Syria; 2003.
Peto J, Collins N, Barfoot R, et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst. 1999;91:943–9.
National Comprehensive Cancer Network: =Clinical practice guidelines in oncology: Genetic/familial high-risk assessment—Breast, ovarian, and pancreatic. https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf
Rouba A, Kaisi N, Al-Chaty E, Badin R, Pals G, Young C, Worsham MJ. Patterns of allelic loss at the BRCA1 locus in Arabic women with breast cancer. Int J Mol Med. 2000;6(5):565–9.
Abdel-Razeq H, Abujamous L, Jadaan D. Patterns and prevalence of germline BRCA1 and BRCA2 mutations among high-risk breast cancer patients in Jordan: a study of 500 patients. J Oncol. 2020;2020:8362179.
Troudi W, Uhrhammer N, Romdhane KB, Sibille C, Amor MB, Khodjet El Khil H, Jalabert T, Mahfoudh W, Chouchane L, Ayed FB, Bignon YJ, Elgaaied AB. Complete mutation screening and haplotype characterization of BRCA1 gene in Tunisian patients with familial breast cancer. Cancer Biomark. 2008;4(1):11–8.
Mahfoudh W, Bouaouina N, Ahmed SB, Gabbouj S, Shan J, Mathew R, Uhrhammer N, Bignon YJ, Troudi W, Elgaaied AB, Hassen E, Chouchane L. Hereditary breast cancer in Middle Eastern and North African (MENA) populations: identification of novel, recurrent and founder BRCA1 mutations in the Tunisian population. Mol Biol Rep. 2012;39(2):1037–46.
El Saghir NS, Zgheib NK, Assi HA, Khoury KE, Bidet Y, Jaber SM, et al. BRCA1 and BRCA2 mutations in ethnic Lebanese Arab women with high hereditary risk breast cancer. Oncologist. 2015;20:357–64.
Jalkh N, Nassar-Slaba J, Chouery E, Salem N, Uhrchammer N, Golmard L, et al. Prevalance of BRCA1 and BRCA2 mutations in familial breast cancer patients in Lebanon. Hered Cancer Clin Pract. 2012;10:7.
Laraqui A, Uhrhammer N, Lahlou-Amine I, Rhaffouli EL, El Baghdadi J, Dehayni M, et al. Mutation screening of the BRCA1 gene in early onset and familial breast/ovarian cancer in Moroccan population. Int J Med Sci. 2013;10:60–7.
Ibrahim SS, Hafez EE, Hashishe MM. Presymptomatic breast cancer in Egypt: role of BRCA1 and BRCA2 tumor suppressor genes mutations detection. J Exp Clin Cancer Res. 2010;29:82–91.
Awadelkarim KD, Aceto GVS, Elhaj A, Morgano A, Mohamedani AA, et al. BRCA1 and BRCA2 status in a central Sudanese series of breast cancer patients: interactions with genetic, ethnic and reproductive factors. Breast Cancer Res Treat. 2007;102:189–99.
Hasan TN, Shafi G, Syed NA, Alsaif MA, Alsaif AA, Alshatwi AA. Lack of association of BRCA1 and BRCA2 variants with breast cancer in an ethnic population of Saudi Arabia, an emerging high-risk area. Asian Pac J Cancer Prev. 2013;14:5671–4.
Troudi W, Uhrhammer N, Romdhane KB, Sibille C, Amor MB, El Khil HK, et al. Complete mutation screening and haplotype characterization of BRCA1 gene in Tunisian patients with familial breast cancer. Cancer Biomark. 2008;4:11–8.
Al-Azri M, Al-Awisi H, Al-Rasbi S, El-Shafie K, Al-Hinai M, Al-Habsi H, et al. Psychosocial impact of breast cancer diagnosis among Omani women. Oman Med J. 2014;29(6):437–44.
Alqaissi NM, Dickerson SS. Exploring common meanings of social support as experienced by Jordanian women with breast cancer. Cancer Nurs. 2010;33(5):353–61.
Doumit MA, El Saghir N, Abu-Saad Huijer H, Kelley JH, Nassar N. Living with breast cancer, a Lebanese experience. Eur J Oncol Nurs. 2010;14(1):42–8.
Elobaid Y, Aw TC, Lim JNW, Hamid S, Grivna M. Breast cancer presentation delays among Arab and national women in the UAE: a qualitative study. SSM Population Health. 2016;2:155–63.
Jassim GA, Whitford DL. Understanding the experiences and quality of life issues of Bahraini women with breast cancer. Soc Sci Med. 2014;107:189–95.
McEwan J, Underwood C, Corbex M. “Injustice! That is the cause”: a qualitative study of the social, economic, and structural determinants of late diagnosis and treatment of breast cancer in Egypt. Cancer Nurs. 2014;37(6):468–75.
Nizamli F, Anoosheh M, Mohammadi E. Experiences of Syrian women with breast cancer regarding chemotherapy: a qualitative study. Nurs Health Sci. 2011;13(4):481–7.
Conflict of Interest
Authors have no conflict of interest to declare.
Editors and Affiliations
Rights and permissions
Open Access This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.
The images or other third party material in this chapter are included in the chapter's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the chapter's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
© 2022 The Author(s)
About this chapter
Cite this chapter
Saadeh, S., Abdel-Razeq, H. (2022). Breast Cancer in the Arab World. In: Al-Shamsi, H.O., Abu-Gheida, I.H., Iqbal, F., Al-Awadhi, A. (eds) Cancer in the Arab World. Springer, Singapore. https://doi.org/10.1007/978-981-16-7945-2_22
Publisher Name: Springer, Singapore
Print ISBN: 978-981-16-7944-5
Online ISBN: 978-981-16-7945-2
eBook Packages: MedicineMedicine (R0)